Glenmede Trust CO Na Protagonist Therapeutics, Inc Transaction History
Glenmede Trust CO Na
- $19.6 Billion
- Q2 2024
A detailed history of Glenmede Trust CO Na transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Glenmede Trust CO Na holds 15,506 shares of PTGX stock, worth $738,395. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,506
Previous 11,451
35.41%
Holding current value
$738,395
Previous $331,000
62.24%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PTGX
# of Institutions
212Shares Held
59.1MCall Options Held
19KPut Options Held
107K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$278 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$274 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$252 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$158 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$154 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.34B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...